Shots:Changjin spoke about the P-I results of their lead candidate, Bofutrelvir to treat acute and long covid. The data was presented at the poster session of the 11th International Conference on ICEID, 2022Changjin also talked about the upcoming formulations of this innovative medicine and the initiation of its BRIGHT study covering the P-II/III…
